CSIMarket
 


Hutchmed china Limited  (HCM)
Other Ticker:  
 

Hutchmed China Limited's Long Term Debt to Equity

HCM's quarterly Long Term Debt to Equity and Long Term Debt, Equity growth


Due to long-term debt repayement of 0% Hutchmed China Limited improved Long Term Debt to Equity in forth quarter 2023 to 0.06, below the company's average Long Term Debt to Equity.

Within Major Pharmaceutical Preparations industry in the forth quarter 2023, 10 other companies have achieved lower Long Term Debt to Equity than Hutchmed China Limited in the IV Quarter 2023. While Long Term Debt to Equity total ranking has deteriorated compared to the third quarter 2023 from 0 to 148 .

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt HCM´s has?
What is the structure of HCM´s Equity?


HCM Long Term Debt to Equity (Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity Change 16.73 % 16.73 % 16.73 % 16.73 % -38.73 %
Y / Y Long Term Debt Change 166.18 % 166.18 % 166.18 % 166.18 % -
Long Term Debt to Equity MRQ 0.06 0.06 0.06 0.06 0.03
HCM's Total Ranking # 148 # 0 # 0 # 0 # 289
Seq. Equity Change 0 % 0 % 0 % 16.73 % 0 %
Seq. Long Term Debt Change 0 % 0 % 0 % 166.18 % 0 %



Long Term Debt to Equity forth quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 11
Healthcare Sector # 21
Overall Market # 148


Long Term Debt to Equity Statistics
High Average Low
0.09 0.06 0.03
(Dec 31 2019)   (Dec 31 2022)




Financial Statements
Hutchmed China Limited's Equity $ 743 Millions Visit HCM's Balance sheet
Hutchmed China Limited's Long Term Debt $ 48 Millions Visit HCM's Balance sheet
Source of HCM's Sales Visit HCM's Sales by Geography


Cumulative Hutchmed China Limited's Long Term Debt to Equity

HCM's Long Term Debt to Equity for the trailling 12 Months

HCM Long Term Debt to Equity

(Dec 31 2023)
IV. Quarter
0
III. Quarter
0
II. Quarter
0
I. Quarter
(Dec 31 2022)
IV. Quarter
Y / Y Equity TTM Growth 16.73 % 16.73 % 16.73 % 16.73 % -38.73 %
Y / Y Long Term Debt TTM Growth 166.18 % 166.18 % 166.18 % 166.18 % -
Long Term Debt to Equity TTM 0.06 0.06 0.05 0.04 0.03
Total Ranking TTM # 255 # 0 # 0 # 0 # 13
Seq. Equity TTM Growth 0 % 0 % 0 % 16.73 % 0 %
Seq. Long Term Debt TTM Growth 0 % 0 % 0 % 166.18 % 0 %


On the trailing twelve months basis Due to long-term debt repayement of 0% Hutchmed China Limited has not changed Long Term Debt to Equity in the 12 months ending in IV Quarter 2023 to 0.06, above the Hutchmed China Limited's average Long Term Debt to Equity.
Long Term Debt to Equity is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry 13, during the past 12 months, other companies have achieved lower Long Term Debt to Equity than Hutchmed China Limited. While Long Term Debt to Equity total ranking has deteriorated during the twelve months ending in the IV Quarter 2023, compared to the prior period, from 0 to 255.

Explain Long Term Debt to Equity Ratio?
How much Long Term Debt HCM´s has?
What is the structure of HCM´s Equity?

TTM Long Term Debt to Equity Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 14
Healthcare Sector # 39
Within the Market # 255


trailing twelve months Long Term Debt to Equity Statistics
High Average Low
0.09 0.05 0
(Dec 31 2019)   0




Companies with similar Long Term Debt to Equity in the quarter ending Dec 31 2023, within Major Pharmaceutical Preparations Industry Long Term Debt to EquityDec 31 2023 MRQ Long Term DebtDec 31 2023 MRQ Equity
Capricor Therapeutics inc   0.15 $ 3.376  Millions$ 22.601  Millions
Clene Inc   0.14 $ 1.894  Millions$ 13.390  Millions
Kamada Ltd   0.14 $ 34.379  Millions$ 244.021  Millions
Compass Pathways Plc  0.13 $ 28.757  Millions$ 225.744  Millions
Ainos Inc   0.12 $ 3.000  Millions$ 24.448  Millions
Biomarin Pharmaceutical Inc  0.12 $ 593.095  Millions$ 4,951.549  Millions
Earth Science Tech Inc   0.10 $ 0.216  Millions$ 2.159  Millions
Bicycle Therapeutics Plc  0.08 $ 30.698  Millions$ 370.932  Millions
Regeneron Pharmaceuticals Inc   0.08 $ 1,982.900  Millions$ 25,973.100  Millions
Hutchmed china Limited  0.06 $ 48.189  Millions$ 743.387  Millions
Roivant Sciences Ltd   0.06 $ 403.337  Millions$ 6,584.582  Millions
Renovaro Inc   0.06 $ 2.569  Millions$ 43.596  Millions
Beigene ltd   0.06 $ 197.618  Millions$ 3,537.327  Millions
Elite Pharmaceuticals Inc   0.05 $ 2.407  Millions$ 46.414  Millions
United Therapeutics Corporation  0.05 $ 300.000  Millions$ 5,984.800  Millions
Xencor Inc  0.02 $ 14.642  Millions$ 669.133  Millions
Igc Pharma Inc   0.02 $ 0.138  Millions$ 9.053  Millions
Gossamer Bio Inc   0.01 $ 0.814  Millions$ 62.769  Millions

Date modified: 2024-02-28T21:10:39+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com